Abstract 2604
Background
Regorafenib is a multikinase inhibitor that improved overall survival (OS) and time to progression (TTP) in patients with HCC who progressed during sorafenib treatment in the phase 3 RESORCE trial. This exploratory analysis evaluated the impact of SNPs on regorafenib treatment benefit (OS and TTP) and the occurrence of hand–foot skin reaction (HFSR) in the RESORCE trial.
Methods
Genotyping of 187 SNPs was performed on whole blood DNA from 330/573 (58%) patients from RESORCE using a custom NimbleGen™ kit and sequencing libraries that were made using NimbleGen™ KAPA Hyper construction kits. The prognostic and predictive effects of the SNPs, as well as the impact on the occurrence of grade ≥1 HFSR, were assessed using Cox proportional hazards regression with Breslow tie handling or logistic regression, respectively. Models were adjusted for clinical covariates as determined by Akaike information criterion (AIC)-based selection and adjusted for population stratification. P values were corrected for multiple testing using Bonferroni correction and deemed significant at an adjusted α ≤ 0.05.
Results
The overall RESORCE and biomarker cohorts were generally similar for demographic variables (except the latter had a smaller proportion of Asian patients) and outcomes. None of the assessed SNPs were prognostic or predictive of OS. In contrast, 6 SNPs (positioned in the UGT1A1, VEGFC, and TIE2 genes) were prognostic for TTP; SNP rs4148323 in the UGT1A1 gene was predictive for TTP (HR 0.24, 95% CI 0.12–0.49; adjusted p = 0.012). The rs1547651 SNP in the VEGFA gene showed a significant prognostic effect on the occurrence of grade ≥1 HFSR (odds ratio [OR] 0.04, 95% CI 0.01–0.19; adjusted p = 0.037), while the rs114681547 SNP, also in the VEGFA gene, showed a predictive effect (OR 26.23, 95% CI 5.39–197.96; adjusted p = 0.038).
Conclusions
These exploratory results suggest that the detected SNP biomarkers may be candidates for future research to gain deeper understanding of the biological mechanisms determining clinical benefit of regorafenib treatment in HCC.
Clinical trial identification
NCT01774344.
Legal entity responsible for the study
Bayer.
Funding
Bayer.
Editorial Acknowledgement
Editorial assistance in the preparation of this abstract was provided by Katrin Gudmundsdottir of SuccinctChoice Medical Communications (London, UK), with financial support from Bayer.
Disclosure
K. Köchert, G. Meinhardt, M. Teufel: Stock ownership, Employee: Bayer. J. Bruix: Grants, Research support: Bayer; Advisory board: Bayer, AbbVie, Bristol-Myers Squibb, Novartis, Roche, Onxeo, Terumo, Sirtex and BTG; Consulting: Daiichi Sankyo, ArQule, Bayer, AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Lilly, Kowa, Novartis, Roche, Onxeo, Terumo, Sirtex.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract